This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Aanbod, overtoewijzing en noteringHet gewijzigde aanbod omvat tot € 20 miljoen aan nieuw uit te geven aandelen en tot 82.562 aandelen, nieuw uit te geven…
Not for release, publication or distribution in or into the United States, Canada, Australia, Japan or any other jurisdiction where this is not allowed pursuant…
“We are excited about this opportunity to apply our adenoviral collections and screening expertise to CFFT’s target discovery program,” said Onno van de Stolpe, CEO…
The project is part of a research program sponsored by the Dutch government through SenterNovem and will combine the capabilities and know-how of TNO and…
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer’s disease programs….
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer’s disease programs….
The SilenceSelectTM collection is offered by Galádeno, Galapagos’ genomics services unit. The adenoviral collection contains siRNA knock-down sequences targeting over 4,000 human drugable transcripts, where…
About Galapagos Genomics NVGalapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer’s disease and asthma. Proprietary targets and…